Reviews Doxazosin Mesylate Extended Release Tablets


No reviews yet.

Cardura XL Drug Description
CARDURA® XL
(doxazosin mesylate) Extended Release Tablets
DRUG DESCRIPTION
CARDURA® XL (doxazosin mesylate extended release tablets) contains doxazosin
mesylate which is a quinazoline compound with the chemical name 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4benzodioxan-2-ylcarbonyl)
piperazine methanesulfonate. The empirical formula for doxazosin mesylate is
C23H25N5O5 •CH4O3S
and the molecular weight is 547.6. It has the following structure:








CARDURA XL is an extended release tablet for oral use and is designed to deliver
4 or 8 mg of doxazosin as the free base. Each 4 and 8 mg tablet contains 5.1
and 10.2 mg doxazosin mesylate (includes a 5% overage) to provide 4 and 8 mg
doxazosin as a free base, respectively. The inactive ingredients for CARDURA
XL are: polyethylene oxide, sodium chloride, hypromellose, red ferric oxide,
titanium dioxide, magnesium stearate, cellulose acetate, Macrogol®, pharmaceutical
glaze, and black iron oxide.
CARDURA XL System Components and Performance
CARDURA XL is similar in appearance to a conventional tablet. It consists,
however, of an osmotically active drug core surrounded by a semipermeable membrane.
The core itself is divided into two layers: an “active” layer containing the
drug, and a “push” layer containing pharmacologically inert (but osmotically
active) components. The membrane surrounding the tablet is permeable to water
but not to drug or osmotic excipients. As water from the gastrointestinal tract
enters the tablet, pressure increases in the osmotic layer and “pushes” against
the drug layer, resulting in the release of drug through a small, laser-drilled
orifice in the membrane on the drug side of the tablet.
CARDURA XL utilizes GITS (Gastrointestinal Therapeutic System) which is designed
to provide a controlled rate of delivery of doxazosin into the gastrointestinal lumen which is independent of pH or gastrointestinal (GI) motility. The function
of CARDURA XL depends upon the existence of an osmotic gradient between the
contents of the bi-layer core and fluid in the GI tract. Drug delivery is essentially
constant as long as the osmotic gradient remains constant, and then gradually
falls to zero. The biologically inert components of the tablet remain intact
during GI transit and are eliminated in the feces as an insoluble shell.Last reviewed on RxList: 4/1/2010




Cardura XL Drug Description
CARDURA® XL
(doxazosin mesylate) Extended Release Tablets
DRUG DESCRIPTION
CARDURA® XL (doxazosin mesylate extended release tablets) contains doxazosin
mesylate which is a quinazoline compound with the chemical name 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4benzodioxan-2-ylcarbonyl)
piperazine methanesulfonate. The empirical formula for doxazosin mesylate is
C23H25N5O5 •CH4O3S
and the molecular weight is 547.6. It has the following structure:








CARDURA XL is an extended release tablet for oral use and is designed to deliver
4 or 8 mg of doxazosin as the free base. Each 4 and 8 mg tablet contains 5.1
and 10.2 mg doxazosin mesylate (includes a 5% overage) to provide 4 and 8 mg
doxazosin as a free base, respectively. The inactive ingredients for CARDURA
XL are: polyethylene oxide, sodium chloride, hypromellose, red ferric oxide,
titanium dioxide, magnesium stearate, cellulose acetate, Macrogol®, pharmaceutical
glaze, and black iron oxide.
CARDURA XL System Components and Performance
CARDURA XL is similar in appearance to a conventional tablet. It consists,
however, of an osmotically active drug core surrounded by a semipermeable membrane.
The core itself is divided into two layers: an “active” layer containing the
drug, and a “push” layer containing pharmacologically inert (but osmotically
active) components. The membrane surrounding the tablet is permeable to water
but not to drug or osmotic excipients. As water from the gastrointestinal tract
enters the tablet, pressure increases in the osmotic layer and “pushes” against
the drug layer, resulting in the release of drug through a small, laser-drilled
orifice in the membrane on the drug side of the tablet.
CARDURA XL utilizes GITS (Gastrointestinal Therapeutic System) which is designed
to provide a controlled rate of delivery of doxazosin into the gastrointestinal lumen which is independent of pH or gastrointestinal (GI) motility. The function
of CARDURA XL depends upon the existence of an osmotic gradient between the
contents of the bi-layer core and fluid in the GI tract. Drug delivery is essentially
constant as long as the osmotic gradient remains constant, and then gradually
falls to zero. The biologically inert components of the tablet remain intact
during GI transit and are eliminated in the feces as an insoluble shell.Last reviewed on RxList: 4/1/2010




Cardura XL Drug Description
CARDURA® XL
(doxazosin mesylate) Extended Release Tablets
DRUG DESCRIPTION
CARDURA® XL (doxazosin mesylate extended release tablets) contains doxazosin
mesylate which is a quinazoline compound with the chemical name 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4benzodioxan-2-ylcarbonyl)
piperazine methanesulfonate. The empirical formula for doxazosin mesylate is
C23H25N5O5 •CH4O3S
and the molecular weight is 547.6. It has the following structure:








CARDURA XL is an extended release tablet for oral use and is designed to deliver
4 or 8 mg of doxazosin as the free base. Each 4 and 8 mg tablet contains 5.1
and 10.2 mg doxazosin mesylate (includes a 5% overage) to provide 4 and 8 mg
doxazosin as a free base, respectively. The inactive ingredients for CARDURA
XL are: polyethylene oxide, sodium chloride, hypromellose, red ferric oxide,
titanium dioxide, magnesium stearate, cellulose acetate, Macrogol®, pharmaceutical
glaze, and black iron oxide.
CARDURA XL System Components and Performance
CARDURA XL is similar in appearance to a conventional tablet. It consists,
however, of an osmotically active drug core surrounded by a semipermeable membrane.
The core itself is divided into two layers: an “active” layer containing the
drug, and a “push” layer containing pharmacologically inert (but osmotically
active) components. The membrane surrounding the tablet is permeable to water
but not to drug or osmotic excipients. As water from the gastrointestinal tract
enters the tablet, pressure increases in the osmotic layer and “pushes” against
the drug layer, resulting in the release of drug through a small, laser-drilled
orifice in the membrane on the drug side of the tablet.
CARDURA XL utilizes GITS (Gastrointestinal Therapeutic System) which is designed
to provide a controlled rate of delivery of doxazosin into the gastrointestinal lumen which is independent of pH or gastrointestinal (GI) motility. The function
of CARDURA XL depends upon the existence of an osmotic gradient between the
contents of the bi-layer core and fluid in the GI tract. Drug delivery is essentially
constant as long as the osmotic gradient remains constant, and then gradually
falls to zero. The biologically inert components of the tablet remain intact
during GI transit and are eliminated in the feces as an insoluble shell.Last reviewed on RxList: 4/1/2010




Cardura XL Drug Description
CARDURA® XL
(doxazosin mesylate) Extended Release Tablets
DRUG DESCRIPTION
CARDURA® XL (doxazosin mesylate extended release tablets) contains doxazosin
mesylate which is a quinazoline compound with the chemical name 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4benzodioxan-2-ylcarbonyl)
piperazine methanesulfonate. The empirical formula for doxazosin mesylate is
C23H25N5O5 •CH4O3S
and the molecular weight is 547.6. It has the following structure:








CARDURA XL is an extended release tablet for oral use and is designed to deliver
4 or 8 mg of doxazosin as the free base. Each 4 and 8 mg tablet contains 5.1
and 10.2 mg doxazosin mesylate (includes a 5% overage) to provide 4 and 8 mg
doxazosin as a free base, respectively. The inactive ingredients for CARDURA
XL are: polyethylene oxide, sodium chloride, hypromellose, red ferric oxide,
titanium dioxide, magnesium stearate, cellulose acetate, Macrogol®, pharmaceutical
glaze, and black iron oxide.
CARDURA XL System Components and Performance
CARDURA XL is similar in appearance to a conventional tablet. It consists,
however, of an osmotically active drug core surrounded by a semipermeable membrane.
The core itself is divided into two layers: an “active” layer containing the
drug, and a “push” layer containing pharmacologically inert (but osmotically
active) components. The membrane surrounding the tablet is permeable to water
but not to drug or osmotic excipients. As water from the gastrointestinal tract
enters the tablet, pressure increases in the osmotic layer and “pushes” against
the drug layer, resulting in the release of drug through a small, laser-drilled
orifice in the membrane on the drug side of the tablet.
CARDURA XL utilizes GITS (Gastrointestinal Therapeutic System) which is designed
to provide a controlled rate of delivery of doxazosin into the gastrointestinal lumen which is independent of pH or gastrointestinal (GI) motility. The function
of CARDURA XL depends upon the existence of an osmotic gradient between the
contents of the bi-layer core and fluid in the GI tract. Drug delivery is essentially
constant as long as the osmotic gradient remains constant, and then gradually
falls to zero. The biologically inert components of the tablet remain intact
during GI transit and are eliminated in the feces as an insoluble shell.Last reviewed on RxList: 4/1/2010




Cardura XL Drug Description
CARDURA® XL
(doxazosin mesylate) Extended Release Tablets
DRUG DESCRIPTION
CARDURA® XL (doxazosin mesylate extended release tablets) contains doxazosin
mesylate which is a quinazoline compound with the chemical name 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4benzodioxan-2-ylcarbonyl)
piperazine methanesulfonate. The empirical formula for doxazosin mesylate is
C23H25N5O5 •CH4O3S
and the molecular weight is 547.6. It has the following structure:








CARDURA XL is an extended release tablet for oral use and is designed to deliver
4 or 8 mg of doxazosin as the free base. Each 4 and 8 mg tablet contains 5.1
and 10.2 mg doxazosin mesylate (includes a 5% overage) to provide 4 and 8 mg
doxazosin as a free base, respectively. The inactive ingredients for CARDURA
XL are: polyethylene oxide, sodium chloride, hypromellose, red ferric oxide,
titanium dioxide, magnesium stearate, cellulose acetate, Macrogol®, pharmaceutical
glaze, and black iron oxide.
CARDURA XL System Components and Performance
CARDURA XL is similar in appearance to a conventional tablet. It consists,
however, of an osmotically active drug core surrounded by a semipermeable membrane.
The core itself is divided into two layers: an “active” layer containing the
drug, and a “push” layer containing pharmacologically inert (but osmotically
active) components. The membrane surrounding the tablet is permeable to water
but not to drug or osmotic excipients. As water from the gastrointestinal tract
enters the tablet, pressure increases in the osmotic layer and “pushes” against
the drug layer, resulting in the release of drug through a small, laser-drilled
orifice in the membrane on the drug side of the tablet.
CARDURA XL utilizes GITS (Gastrointestinal Therapeutic System) which is designed
to provide a controlled rate of delivery of doxazosin into the gastrointestinal lumen which is independent of pH or gastrointestinal (GI) motility. The function
of CARDURA XL depends upon the existence of an osmotic gradient between the
contents of the bi-layer core and fluid in the GI tract. Drug delivery is essentially
constant as long as the osmotic gradient remains constant, and then gradually
falls to zero. The biologically inert components of the tablet remain intact
during GI transit and are eliminated in the feces as an insoluble shell.Last reviewed on RxList: 4/1/2010





Other reviews about Doxazosin Mesylate Extended Release Tablets on wordpress

Pfizer - Business
  by El Horror
About - Merged with Warner-Lambert in 2000. $90 billion, 3th major M&A in the last 20 years (-2009). - Merged with Pharmacia in 2003. $59,515 million, 8th major M&A in […]


For there might not have bee
  by wpualjandnmtc
He still rode the board now and then, when the surf was high. It tasted like a combination of paper and library paste. Judds paper on the Volcanoes […]


Ilkley, Yorkshire, Saturday [Novembe
  by jigvpufrils
Thats where my car got the best mileage. Martin History of the Dog 1845 page 203. And theres one thing I clean forgot. I wrinkled my brow, […]


In the center of the clearing stood a
  by lnnuqdgwhilcec
It will be quite delightful, I declare! Then a declaration was made on the part of the Czar, stating the reasons which had induced his majesty to depose […]


Paul went home and busied himself sup
  by uvlsrltbrijyqd
Let this dragon roar first, Hancock interposed. Micky found herself staring up expectantly at the ceiling, and she realized that the timing of the power outage, just as […]


It was not my purpose to join you,
  by uqrvuqebexlikqq
to find an author with originality! Self, self, selfthats all it is with themand ignorance. There isnt a ruler in the Periphery now that wouldnt sooner cut his […]


Ellies little Schwinn w
  by byahyqpbltmegpe
Oh, men stop them all along the river, and put them into booms, and then fasten them together in rafts. I have made for you a song, DANNY […]


Wonder what my second in co
  by pqegmccdfpdrs
After a century the noon whistle blew. But if you only have two chronometers, how can you tell which has gone wrong? Have you not heard […]


Why, we should not have h
  by dferifnfpibanbi
McDowell subsided into his chair. It has come to me at last, andmy God! But th parson were a steadygaited sort o chap, and Jesse were strong o […]


CHAPTER 33 PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES
  by medtextfree
CHAPTER 33 PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES Practice of Geriatrics CHAPTER 33 PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES David Gordon Lichter, M.B., Ch.B., F.R.A.C.P. Pathophysiology Clinical Assessment Differential Diagnosis of Parkinson's Disease Management of Parkinson's Disease Institutionalization […]



Other reviews about Doxazosin Mesylate Extended Release Tablets on web:

Doxazosin Mesylate Oral tablet, extended-release To return to the main entry click here . What is this medicine? DOXAZOSIN (dox AY zoe sin) is an Doxazosin Mesylate Oral tablet, extended-release: Information from ...


Precautions for CARDURA XL, drug interactions, information for patients, and considerations for special populations CARDURAテδづつョ XL (doxazosin mesylate extended release tablets) Precautions


Doxazosin Mesylate; Generic Available. Yes: Excludes extended release tablet. Canadian Brand Names. Alti-Doxazosin ... Tablets (Doxazosin Mesylate) 1 mg (30): $17.99. 2 mg (30 ... Doxazosin: Drug Information Provided by Lexi-Comp: Merck Manual ...


CARDURA XL is an extended release tablet for oral use. Each 4 and 8 mg tablet contains 5.1 and 10.2 mg doxazosin mesylate (includes a 5% overage) to provide 4 and 8 mg doxazosin as ... CARDURAテδづつョ XL (doxazosin mesylate extended release tablets) Description


1 CARDURA テδづつョ XL (doxazosin mesylate extended release tablets) DESCRIPTION CARDURA テδづつョ XL (doxazosin mesylate extended release tablets) contains doxazosin mesylate which is a quinazoline ... CARDURAテδづつョXL


Attention, chocolate lovers: You may not be able to help yourselves. Swiss and British scientists have linked the widespread love of chocolate to a chemical "signature" that may be ... CARDURAテδづつョ XL(doxazosin mesylate extended release tablets) Drug ...


Doxazosin Extended-Release Tablets may cause dizziness, lightheadedness, or fainting; alcohol, hot ... Doxazosin mesylate 1 mg Doxazosin Extended-Release Tablets Facts and Comparisons at Drugs.com


Doxazosin Mesylate Pronunciation: (dox-AZ-oh-sin MEH-sin-LATE) ... - Tablets, extended-release 4 mg - Tablets, extended-release 8 mg. Apo-Doxazosin (Canada) Complete Doxazosin Mesylate information from Drugs.com


Doxazosin extended-release tablets (below) Doxazosin Mesylate Oral tablet; Doxazosin Mesylate Oral tablet, extended-release; Espaテδεつアol: Doxazosテδεつュn Mesilato, Tableta oral Doxazosin: Definition from Answers.com


Learn about the prescription medication Cardura XL (Doxazosin Mesylate Extended Release Tablets), drug uses, dosage, side effects, drug interactions, warnings, reviews and ... Cardura XL (Doxazosin Mesylate Extended Release Tablets) Drug ...





Featured Reviews

Reviews Pentobarbital

Nembutal Drug Description NEMBUTAL® Sodium Solution (pentobarbital sodium) Injection, USP DO NOT USE IF MATERIAL HAS PRECIPITATED DRUG DESCRIPTION What are the possible side effects of pentobarbital (Nembutal Sodium)? Get emergency...
Read More  |  Review This
Reviews Norgestrel And Ethinyl Estradiol

Lo Ovral Drug Description LO/OVRAL®-28 (norgestrel and ethinyl estradiol) Tablets Patients should be counseled that oral contraceptives do not protect against transmission of HIV (AIDS) and other sexually transmitted diseases (STDs)...
Read More  |  Review This
Reviews Chlorambucil

Leukeran Drug Description LEUKERAN (chlorambucil) Tablets WARNING LEUKERAN (chlorambucil) can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans....
Read More  |  Review This
Reviews Mirena

Mirena Drug Description Mirena (levonorgestrel-releasing) Intrauterine System DRUG DESCRIPTION What are the possible side effects of levonorgestrel intrauterine system (Mirena)? Get emergency medical help if you have severe pain...
Read More  |  Review This
Reviews Skelid

Skelid Drug Description SKELID® (tiludronate disodium) DRUG DESCRIPTION What are the possible side effects of tiludronate (Skelid)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....